Handel 10x Genomics, Inc. - TXG CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.14 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024874% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.002651% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 51.97 |
Åben* | 53.18 |
1-Års Ændring* | -28.68% |
Dagens Spænd* | 53.18 - 56.09 |
52-Ugers Spænd | 23.81-83.34 |
Gennemsnitlig Volumen (10 dage) | 754.85K |
Gennemsnitlig Volumen (3 måneder) | 21.21M |
Market Cap | 6.00B |
P/E-forhold | -100.00K |
Udestående aktier | 115.36M |
Omsætning | 516.41M |
EPS | -1.46 |
Dividend (Udbytte %) | N/A |
Beta | 1.74 |
Næste indtjeningsopgørelse | May 2, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 55.73 | 3.30 | 6.29% | 52.43 | 56.16 | 52.01 |
Mar 30, 2023 | 51.97 | 0.76 | 1.48% | 51.21 | 52.32 | 51.07 |
Mar 29, 2023 | 50.69 | 1.41 | 2.86% | 49.28 | 50.98 | 49.00 |
Mar 28, 2023 | 48.81 | -0.45 | -0.91% | 49.26 | 49.42 | 48.27 |
Mar 27, 2023 | 49.70 | -0.68 | -1.35% | 50.38 | 51.52 | 49.29 |
Mar 24, 2023 | 50.12 | 2.16 | 4.50% | 47.96 | 50.30 | 47.65 |
Mar 23, 2023 | 48.97 | 0.03 | 0.06% | 48.94 | 51.49 | 48.48 |
Mar 22, 2023 | 48.69 | -1.39 | -2.78% | 50.08 | 51.08 | 48.61 |
Mar 21, 2023 | 50.03 | 1.83 | 3.80% | 48.20 | 50.25 | 47.91 |
Mar 20, 2023 | 47.76 | 0.30 | 0.63% | 47.46 | 48.56 | 46.76 |
Mar 17, 2023 | 48.08 | -1.09 | -2.22% | 49.17 | 49.71 | 47.66 |
Mar 16, 2023 | 50.25 | 2.49 | 5.21% | 47.76 | 50.90 | 47.60 |
Mar 15, 2023 | 48.54 | 1.45 | 3.08% | 47.09 | 49.32 | 47.08 |
Mar 14, 2023 | 48.63 | 0.07 | 0.14% | 48.56 | 49.52 | 48.06 |
Mar 13, 2023 | 47.44 | 3.47 | 7.89% | 43.97 | 49.32 | 43.97 |
Mar 10, 2023 | 44.93 | -1.55 | -3.33% | 46.48 | 46.49 | 43.15 |
Mar 9, 2023 | 47.00 | -1.65 | -3.39% | 48.65 | 49.98 | 46.93 |
Mar 8, 2023 | 48.95 | 1.16 | 2.43% | 47.79 | 49.49 | 47.24 |
Mar 7, 2023 | 48.16 | 0.10 | 0.21% | 48.06 | 49.75 | 47.48 |
Mar 6, 2023 | 48.39 | -2.30 | -4.54% | 50.69 | 50.80 | 48.13 |
10x Genomics, Inc. Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total omsætning | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Omsætning | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Kost af omsætning, Total | 120.386 | 74.091 | 58.468 | 61.033 | 28.661 |
Bruttofortjeneste | 396.023 | 416.399 | 240.377 | 184.86 | 117.652 |
Totale Driftsudgifter | 684.353 | 542.743 | 834.508 | 276.466 | 257.077 |
Salgs/Generelle/Admin. Udgifter, Total | 298.3 | 257.56 | 199.726 | 130.834 | 87.936 |
Forskning & Udvikling | 265.667 | 211.752 | 570.923 | 83.097 | 109.9 |
Other Operating Expenses, Total | 0 | -0.66 | 1.27 | 1.502 | 30.58 |
Driftsindtægter | -167.944 | -52.253 | -535.663 | -30.573 | -110.764 |
Renteindkomst (Udgift), Netto Ikke-Drift | 6.171 | -0.66 | -0.15 | -0.274 | -1.385 |
Andre, Netto | -0.198 | -0.802 | 1.337 | -0.186 | -0.249 |
Netto Indkomst Før Skat | -161.971 | -53.715 | -534.476 | -31.033 | -112.398 |
Netto Indkomst Efter Skat | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Netto Indkomst Før Ekstra Ting | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Totale Ekstraordinære Ting | |||||
Netto Indkomst | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Fortyndet Netto Indkomst | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Fortyndet Vægtet Gennemsnit Aktier | 113.859 | 110.348 | 101.152 | 96.2416 | 93.8497 |
Fortyndet EPS Uden Ekstraordinære Ting | -1.45795 | -0.52763 | -5.36552 | -0.32471 | -1.19857 |
Fortyndet Normaliseret EPS | -1.45795 | -0.52763 | -5.33904 | -0.32471 | -1.19857 |
Usædvanlig Udgift (Indkomst) | 0 | 0 | 4.121 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total omsætning | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Omsætning | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Kost af omsætning, Total | 36.827 | 30.377 | 27.704 | 25.478 | 27.598 |
Bruttofortjeneste | 119.405 | 100.695 | 86.905 | 89.018 | 115.932 |
Totale Driftsudgifter | 179.328 | 171.068 | 177.726 | 156.231 | 159.36 |
Salgs/Generelle/Admin. Udgifter, Total | 78.887 | 73.401 | 79.337 | 66.675 | 69.877 |
Forskning & Udvikling | 63.614 | 67.29 | 70.685 | 64.078 | 61.885 |
Usædvanlig Udgift (Indkomst) | 0 | 0 | |||
Other Operating Expenses, Total | 0 | 0 | 0 | 0 | |
Driftsindtægter | -23.096 | -39.996 | -63.117 | -41.735 | -15.83 |
Renteindkomst (Udgift), Netto Ikke-Drift | 2.69 | 1.911 | 1.129 | 0.441 | -0.168 |
Andre, Netto | 3.995 | -1.95 | -1.843 | -0.4 | 0.005 |
Netto Indkomst Før Skat | -16.411 | -40.035 | -63.831 | -41.694 | -15.993 |
Netto Indkomst Efter Skat | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Netto Indkomst Før Ekstra Ting | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Netto Indkomst | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Fortyndet Netto Indkomst | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Fortyndet Vægtet Gennemsnit Aktier | 114.767 | 114.112 | 113.575 | 112.966 | 111.913 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Fortyndet Normaliseret EPS | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 747.591 | 774.366 | 480.84 | 106.236 | 68.107 |
Likvider og Kortsigtede Investeringer | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Likvider & Lignende | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Totale Tilgodehavender, Netto | 85.254 | 51.208 | 33.371 | 29.566 | 13.341 |
Accounts Receivable - Trade, Net | 85.254 | 51.208 | 33.371 | 28.088 | 13.341 |
Total Inventory | 59.966 | 29.959 | 15.27 | 8.57 | 4.838 |
Prepaid Expenses | 13.896 | 13.029 | 8.033 | 3.02 | 2.071 |
Total Assets | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Property/Plant/Equipment, Total - Net | 230.41 | 119.823 | 48.821 | 11.127 | 6.925 |
Property/Plant/Equipment, Total - Gross | 279.431 | 150.325 | 67.876 | 25.21 | 17.958 |
Accumulated Depreciation, Total | -49.021 | -30.502 | -19.055 | -14.083 | -11.033 |
Other Long Term Assets, Total | 10.917 | 12.798 | 76.262 | 6.947 | 0.577 |
Total Current Liabilities | 110.357 | 118.126 | 63.049 | 32.362 | 22.141 |
Accounts Payable | 17.351 | 4.709 | 13.028 | 8.792 | 5.443 |
Accrued Expenses | 75.821 | 92.326 | 30.035 | 12.118 | 8.959 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 9.882 | 4.187 | 4.224 | |
Other Current Liabilities, Total | 17.185 | 21.091 | 10.104 | 7.265 | 3.515 |
Total Liabilities | 201.258 | 190.269 | 185.84 | 101.053 | 29.704 |
Total Long Term Debt | 0 | 0 | 19.837 | 25.489 | 6.335 |
Long Term Debt | 0 | 19.837 | 25.489 | 6.335 | |
Other Liabilities, Total | 90.901 | 72.143 | 102.954 | 43.202 | 1.228 |
Total Equity | 817.568 | 739.072 | 420.083 | 23.257 | 45.905 |
Redeemable Preferred Stock | 0 | 243.244 | 158.414 | ||
Common Stock | 0.002 | 0.002 | 0.002 | 0.001 | 0.001 |
Additional Paid-In Capital | 1680.86 | 1544.22 | 682.494 | 11.165 | 6.136 |
Retained Earnings (Accumulated Deficit) | -863.321 | -805.098 | -262.367 | -231.116 | -118.631 |
Other Equity, Total | 0.022 | -0.05 | -0.046 | -0.037 | -0.015 |
Total Liabilities & Shareholders’ Equity | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Total Common Shares Outstanding | 112.515 | 108.486 | 96.2416 | 93.8497 | 93.8497 |
Other Current Assets, Total | 1.028 | 16.567 | |||
Intangibles, Net | 25.397 | 22.354 | |||
Goodwill, Net | 4.511 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 697.335 | 747.591 | 744.104 | 757.174 | 745.716 |
Likvider og Kortsigtede Investeringer | 539.323 | 587.447 | 600.44 | 621.958 | 617.195 |
Likvider & Lignende | 312.487 | 587.447 | 600.44 | 621.958 | 617.195 |
Totale Tilgodehavender, Netto | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Accounts Receivable - Trade, Net | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Total Inventory | 63.697 | 59.966 | 51.141 | 44.087 | 38.507 |
Prepaid Expenses | 17.762 | 13.896 | 14.065 | 13.298 | 14.442 |
Other Current Assets, Total | 0.027 | 1.028 | 0.028 | 18.151 | 18.164 |
Total Assets | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Property/Plant/Equipment, Total - Net | 265.88 | 230.41 | 203.304 | 176.454 | 163.666 |
Property/Plant/Equipment, Total - Gross | 279.431 | 247.698 | 215.665 | 198.415 | |
Accumulated Depreciation, Total | -49.021 | -44.394 | -39.211 | -34.749 | |
Goodwill, Net | 4.511 | 4.511 | 4.511 | 4.511 | 4.511 |
Intangibles, Net | 24.764 | 25.397 | 26.041 | 26.693 | 27.342 |
Other Long Term Assets, Total | 10.761 | 10.917 | 12.612 | 12.747 | 12.798 |
Total Current Liabilities | 94.446 | 110.357 | 100.375 | 113.126 | 120.549 |
Accounts Payable | 18.956 | 17.351 | 17.037 | 16.181 | 15.578 |
Accrued Expenses | 59.913 | 75.821 | 69.92 | 85.598 | 95.307 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.577 | 17.185 | 13.418 | 11.347 | 9.664 |
Total Liabilities | 196.566 | 201.258 | 190.351 | 192.993 | 201.573 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 102.12 | 90.901 | 89.976 | 79.867 | 81.024 |
Total Equity | 806.685 | 817.568 | 800.221 | 784.586 | 752.46 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1714.86 | 1680.86 | 1644.9 | 1612.23 | 1569.06 |
Retained Earnings (Accumulated Deficit) | -905.734 | -863.321 | -844.872 | -827.701 | -816.649 |
Other Equity, Total | -2.443 | 0.022 | 0.194 | 0.058 | 0.048 |
Total Liabilities & Shareholders’ Equity | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Total Common Shares Outstanding | 113.276 | 112.515 | 111.537 | 110.74 | 109.589 |
Kortsigtede Investeringer | 226.836 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | -58.223 | -542.731 | -31.251 | -112.485 | -18.762 |
Likvider Fra Driftsaktiviteter | -21.373 | -217.898 | 34.627 | -76.409 | -10.699 |
Likvider Fra Driftsaktiviteter | 21.118 | 14.012 | 7.066 | 3.905 | 4.305 |
Ikke-Likvide Ting | 103.177 | 361.202 | 14.048 | 4.156 | 1.81 |
Cash Taxes Paid | 8.66 | 0.28 | -0.022 | -0.006 | 0 |
Likvid Rente Betalt | 1.222 | 1.67 | 2.25 | 1.824 | 0.658 |
Ændringer i Driftskapital | -87.445 | -50.381 | 44.764 | 28.015 | 1.948 |
Likvider fra Investeringsaktiviteter | -106.729 | -38.394 | -42.767 | -6.709 | -3.756 |
Kapitaludgifter | -101.278 | -38.394 | -42.767 | -6.709 | -3.756 |
Likvider fra Financieringsaktiviteter | 35.297 | 468.906 | 414.59 | 105.367 | 20.583 |
Financiering af Cash-Flow-Ting | -5.028 | -5.848 | 0 | 0 | |
Udstedelse (Pensionering) af Aktier, Netto | 40.325 | 506.01 | 414.59 | 86.628 | 20.976 |
Udstedelse (Pensionering) af Gæld, Netto | 0 | -31.256 | 0 | 18.739 | -0.393 |
Udenlandsk Børs Effekter | 0.234 | -0.463 | -0.045 | -0.018 | -0.014 |
Netto Ændring i Likviditet | -92.571 | 212.151 | 406.405 | 22.231 | 6.114 |
Andre Investerings-Cash-Flow-Ting, Total | -5.451 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -42.413 | -58.223 | -39.774 | -22.603 | -11.551 |
Cash From Operating Activities | -20.802 | -21.373 | -27.178 | -0.962 | -4.082 |
Cash From Operating Activities | 6.191 | 21.118 | 15.337 | 9.641 | 4.752 |
Non-Cash Items | 28.014 | 103.177 | 74.717 | 47.188 | 17.922 |
Cash Taxes Paid | 2.9 | 8.66 | 8.318 | 7.838 | 6.822 |
Cash Interest Paid | 0.841 | 1.222 | 1.222 | 1.222 | 1.222 |
Changes in Working Capital | -12.594 | -87.445 | -77.458 | -35.188 | -15.205 |
Cash From Investing Activities | -257.558 | -106.729 | -79.111 | -58.884 | -44.316 |
Capital Expenditures | -28.136 | -101.278 | -73.66 | -53.433 | -38.865 |
Other Investing Cash Flow Items, Total | -229.422 | -5.451 | -5.451 | -5.451 | -5.451 |
Cash From Financing Activities | 2.417 | 35.297 | 26.394 | 19.711 | 3.518 |
Financing Cash Flow Items | -5.409 | -5.028 | -5.028 | -5.028 | -5.028 |
Issuance (Retirement) of Stock, Net | 7.826 | 40.325 | 31.422 | 24.739 | 8.546 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Foreign Exchange Effects | -0.018 | 0.234 | 0.316 | 0.199 | 0.193 |
Net Change in Cash | -275.961 | -92.571 | -79.579 | -39.936 | -44.687 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Morgan Stanley Investment Management Inc. (US) | Investment Advisor/Hedge Fund | 9.4813 | 9210082 | -415196 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 8.8556 | 8602235 | 158847 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.6523 | 8404774 | 145652 | 2022-12-31 | LOW |
Paladin Capital Management, LLC | Investment Advisor | 8.3511 | 8112208 | 0 | 2022-03-31 | |
ARK Investment Management LLC | Investment Advisor | 4.4437 | 4316567 | -260247 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.3422 | 4217954 | 207975 | 2022-12-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 3.3012 | 3206783 | -184394 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.2549 | 3161803 | -518131 | 2022-12-31 | LOW |
SRS Investment Management, LLC | Hedge Fund | 3.0939 | 3005427 | 0 | 2022-12-31 | LOW |
Generation Investment Management LLP | Investment Advisor/Hedge Fund | 2.6231 | 2548100 | -57577 | 2022-12-31 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.2421 | 2177988 | -29270 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.1979 | 2135038 | -17833 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.018 | 1960300 | -337642 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.507 | 1463901 | 1108820 | 2022-12-31 | HIGH |
Brown Capital Management, LLC | Investment Advisor | 1.4964 | 1453630 | -161463 | 2022-12-31 | LOW |
Foresite Capital Management, LLC | Private Equity | 1.3985 | 1358528 | -1145000 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3854 | 1345749 | -18168 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3601 | 1321234 | 63324 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.2491 | 1213394 | 999487 | 2022-12-31 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.2158 | 1180996 | 27291 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
10x Genomics, Inc. Company profile
Om 10x Genomics, Inc.
10x Genomics, Inc. er en virksomhed inden for life science-teknologi. Virksomhedens integrerede løsninger omfatter instrumenter, forbrugsvarer og software til analyse af biologiske systemer. Dens produkter omfatter Chromium Single Cell Gene Expression, Single Cell Immune Profiling, Single Cell assay for transposase accessible chromatin (ATAC) + Gene Expression, Single Cell ATAC, Spatial Gene Expression, Spatial Gene Expression, Spatial Multiomics, og Targeted Gene Expression. Dens instrumenter omfatter Chromium X Series, Chromium Connect og Chromium Controller. Dens teknologi Next GEM-teknologi, som omfatter chips og kompatible reagenser, der tilbydes til single cell-produktporteføljen. Dens portefølje af forbrugsstoffer omfatter mikrofluidiske chips, objektglas, reagenser og andre forbrugsstoffer til både Visium- og Chromium-løsninger. Selskabets applikationer omfatter CRISPR-screening (Clustered Regular Interspaced Short Palindromic Repeats), multiomisk cytometri og kortlægning af immunreceptorer.
Industry: | Laboratory Diagnostic & Testing Substances |
6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com